Literature DB >> 24986852

Longterm blood pressure variability in patients with rheumatoid arthritis and its effect on cardiovascular events and all-cause mortality in RA: a population-based comparative cohort study.

Elena Myasoedova1, Cynthia S Crowson2, Abigail B Green1, Eric L Matteson1, Sherine E Gabriel1.   

Abstract

OBJECTIVE: To examine longterm visit-to-visit blood pressure (BP) variability in patients with rheumatoid arthritis (RA) versus non-RA subjects and to assess its effect on cardiovascular (CV) events and mortality in RA.
METHODS: Clinic BP measures were collected in a population-based incident cohort of patients with RA (1987 American College of Rheumatology criteria met between January 1, 1995, and January 1, 2008) and non-RA subjects. BP variability was defined as within-subject SD in systolic and diastolic BP.
RESULTS: The study included 442 patients with RA (mean age 55.5 yrs, 70% females) and 424 non-RA subjects (mean age 55.7 yrs, 69% females). Patients with RA had higher visit-to-visit variability in systolic BP (13.8 ± 4.7 mm Hg) than did non-RA subjects (13.0 ± 5.2 mm Hg, p = 0.004). Systolic BP variability declined after the index date in RA (p < 0.001) but not in the non-RA cohort (p = 0.73), adjusting for age, sex, and calendar year of RA. During the mean followup of 7.1 years, 33 CV events and 57 deaths occurred in the RA cohort. Visit-to-visit systolic BP variability was associated with increased risk of CV events (HR per 1 mm Hg increase in BP variability 1.12, 95% CI 1.01-1.25). Diastolic BP variability was associated with all-cause mortality in RA (HR 1.14, 95% CI 1.03-1.27), adjusting for systolic and diastolic BP, body mass index, smoking, diabetes, dyslipidemia, and use of antihypertensives.
CONCLUSION: Patients with RA had higher visit-to-visit systolic BP variability than did non-RA subjects. There was a significant decline in systolic BP variability after RA incidence. Higher visit-to-visit BP variability was associated with adverse CV outcomes and all-cause mortality in RA.

Entities:  

Keywords:  BLOOD PRESSURE VARIABILITY; RHEUMATOID ARTHRITIS; TRENDS

Mesh:

Substances:

Year:  2014        PMID: 24986852      PMCID: PMC4159667          DOI: 10.3899/jrheum.131170

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases.

Authors:  Hilal Maradit Kremers; Cynthia S Crowson; Sherine E Gabriel
Journal:  Rheum Dis Clin North Am       Date:  2004-11       Impact factor: 2.670

3.  Patterns of cardiovascular risk in rheumatoid arthritis.

Authors:  D H Solomon; N J Goodson; J N Katz; M E Weinblatt; J Avorn; S Setoguchi; C Canning; S Schneeweiss
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

Review 4.  Glucocorticoid-induced hypertension.

Authors:  Julie E Goodwin; David S Geller
Journal:  Pediatr Nephrol       Date:  2011-07-09       Impact factor: 3.714

5.  Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk.

Authors:  Branislav Milovanović; Ljudmila Stojanović; Nebojsa Milićevik; Karin Vasić; Bojko Bjelaković; Mirjana Krotin
Journal:  Srp Arh Celok Lek       Date:  2010 Jan-Feb       Impact factor: 0.207

Review 6.  Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

Authors:  Deborah P M Symmons; Sherine E Gabriel
Journal:  Nat Rev Rheumatol       Date:  2011-05-31       Impact factor: 20.543

7.  The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.

Authors:  Paulo J Nicola; Hilal Maradit-Kremers; Véronique L Roger; Steven J Jacobsen; Cynthia S Crowson; Karla V Ballman; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2005-02

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 9.  Hypertension in rheumatoid arthritis.

Authors:  V F Panoulas; G S Metsios; A V Pace; H John; G J Treharne; M J Banks; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2008-05-08       Impact factor: 7.580

10.  Cardiovascular disease in rheumatoid arthritis: a systematic literature review in latin america.

Authors:  Juan Camilo Sarmiento-Monroy; Jenny Amaya-Amaya; Juan Sebastián Espinosa-Serna; Catalina Herrera-Díaz; Juan-Manuel Anaya; Adriana Rojas-Villarraga
Journal:  Arthritis       Date:  2012-10-31
View more
  3 in total

1.  Frequency and Predictors of Communication About High Blood Pressure in Rheumatoid Arthritis Visits.

Authors:  Christie Michels Bartels; Heather Johnson; Katya Alcaraz Voelker; Alexis Ogdie; Patrick McBride; Elizabeth A Jacobs; Ying-Qi Zhao; Maureen Smith
Journal:  J Clin Rheumatol       Date:  2018-06       Impact factor: 3.517

2.  Medication adherence and visit-to-visit variability of systolic blood pressure in African Americans with chronic kidney disease in the AASK trial.

Authors:  K Hong; P Muntner; I Kronish; D Shilane; T I Chang
Journal:  J Hum Hypertens       Date:  2015-04-02       Impact factor: 3.012

3.  Association of Urinary Potassium Excretion with Blood Pressure Variability and Cardiovascular Outcomes in Patients with Pre-Dialysis Chronic Kidney Disease.

Authors:  Sang Heon Suh; Su Hyun Song; Tae Ryom Oh; Hong Sang Choi; Chang Seong Kim; Eun Hui Bae; Kook-Hwan Oh; Joongyub Lee; Seung Hyeok Han; Yeong Hoon Kim; Dong-Wan Chae; Seong Kwon Ma; Soo Wan Kim
Journal:  Nutrients       Date:  2021-12-13       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.